312 related articles for article (PubMed ID: 27662014)
21. Congenital ADAMTS13 deficiency: a rare mimicker of immune thrombocytopenic purpura.
Quintero V; Garcia-Pose A; Barrios-Tascon A; Pacheco-Cumani M
J Pediatr Hematol Oncol; 2014 Nov; 36(8):653-5. PubMed ID: 24942015
[TBL] [Abstract][Full Text] [Related]
22. Structural and functional correlation of ADAMTS13.
Dong JF
Curr Opin Hematol; 2007 May; 14(3):270-6. PubMed ID: 17414218
[TBL] [Abstract][Full Text] [Related]
23. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
[TBL] [Abstract][Full Text] [Related]
24. Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura.
Tsai HM
Int J Hematol; 2002 Aug; 76 Suppl 2():132-8. PubMed ID: 12430913
[TBL] [Abstract][Full Text] [Related]
25. ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.
Tersteeg C; Verhenne S; Roose E; Schelpe AS; Deckmyn H; De Meyer SF; Vanhoorelbeke K
Expert Rev Hematol; 2016; 9(2):209-21. PubMed ID: 26581428
[TBL] [Abstract][Full Text] [Related]
26. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Furlan M; Robles R; Galbusera M; Remuzzi G; Kyrle PA; Brenner B; Krause M; Scharrer I; Aumann V; Mittler U; Solenthaler M; Lämmle B
N Engl J Med; 1998 Nov; 339(22):1578-84. PubMed ID: 9828245
[TBL] [Abstract][Full Text] [Related]
27. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
28. ADAMTS-13 antigen and activity levels in thrombocytopenic disorders including thrombotic thrombocytopenic purpura in Kuwait.
Al-Awadhi AM; Jadaon MM; Al-Jafar HA; Al-Wazzan HJ
Acta Haematol; 2011; 125(3):160-6. PubMed ID: 21196718
[TBL] [Abstract][Full Text] [Related]
29. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
Polito MG; Kirsztajn GM
J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
[TBL] [Abstract][Full Text] [Related]
30. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring.
Mannucci PM; Cugno M
Thromb Res; 2015 Nov; 136(5):851-4. PubMed ID: 26386489
[TBL] [Abstract][Full Text] [Related]
31. Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura.
Deforche L; Tersteeg C; Roose E; Vandenbulcke A; Vandeputte N; Pareyn I; De Cock E; Rottensteiner H; Deckmyn H; De Meyer SF; Vanhoorelbeke K
PLoS One; 2016; 11(8):e0160388. PubMed ID: 27479501
[TBL] [Abstract][Full Text] [Related]
32. CD(+)(4)CD(+)(25) Treg cells in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus patients.
Huang H; Sun W; Liang Y; Long XD; Peng Y; Liu Z; Wen X; Jia M
Ren Fail; 2014 Sep; 36(8):1263-7. PubMed ID: 24990576
[TBL] [Abstract][Full Text] [Related]
33. Acquired thrombotic thrombocytopenic purpura. Development of an autoimmune response.
Schaller M; Studt JD; Voorberg J; Kremer Hovinga JA
Hamostaseologie; 2013 May; 33(2):121-30. PubMed ID: 23443151
[TBL] [Abstract][Full Text] [Related]
34. A 9-month-old infant with acquired idiopathic thrombotic thrombocytopenic purpura caused by inhibitory IgG-autoantibody to ADAMTS13.
Sato A; Hoshi Y; Onuma M; Sato R; Tsunematsu Y; Isonishi A; Matsumoto M; Fujimura Y; Imaizumi M
Pediatr Hematol Oncol; 2010 Feb; 27(1):53-8. PubMed ID: 20121555
[TBL] [Abstract][Full Text] [Related]
35. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura.
Kremer Hovinga JA; Studt JD; Demarmels Biasiutti F; Solenthaler M; Alberio L; Zwicky C; Fontana S; Taleghani BM; Tobler A; Lämmle B
Haematologica; 2004 Mar; 89(3):320-4. PubMed ID: 15020271
[TBL] [Abstract][Full Text] [Related]
36. Pathogenesis of thrombotic thrombocytopenic purpura.
Raife TJ
Curr Hematol Rep; 2003 Mar; 2(2):133-8. PubMed ID: 12901144
[TBL] [Abstract][Full Text] [Related]
37. The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
George JN
Clin Adv Hematol Oncol; 2005 Aug; 3(8):627-32. PubMed ID: 16167049
[TBL] [Abstract][Full Text] [Related]
38. ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura.
Manea M; Kristoffersson A; Tsai HM; Zhou W; Winqvist I; Oldaeus G; Billström R; Björk P; Holmberg L; Karpman D
Eur J Pediatr; 2007 Mar; 166(3):249-57. PubMed ID: 17187257
[TBL] [Abstract][Full Text] [Related]
39. Acquired thrombotic thrombocytopenic purpura due to antibody-mediated ADAMTS13 deficiency precipitated by a localized Castleman's disease: a case report.
Benevides TC; Orsi FA; Colella MP; Percout Pde O; Moura MS; Dias MA; Lins BD; Paula EV; Vassallo J; Annichino-Bizzachi J
Platelets; 2015; 26(3):263-6. PubMed ID: 24853254
[TBL] [Abstract][Full Text] [Related]
40. ADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura.
Gunther K; Garizio D; Nesara P
Transfusion; 2007 Sep; 47(9):1710-6. PubMed ID: 17725738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
